Literature DB >> 30518651

Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Yao-Qing Chen1, Linda Yu-Ling Lan2, Min Huang1, Carole Henry1, Patrick C Wilson3,2.   

Abstract

Hemagglutinin (HA) stalk-reactive antibodies are the basis of several current "one-shot" universal influenza vaccine efforts because they protect against a wide spectrum of influenza virus strains. The appreciated mechanism of protection by HA stalk-reactive antibodies is to inhibit HA stalk reconfiguration, blocking viral fusion and entry. This study shows that HA stalk-reactive antibodies also inhibit neuraminidase (NA) enzymatic activity, prohibiting viral egress. NA inhibition (NI) was evident for an attached substrate but not for unattached small-molecule cleavage of sialic acid. This finding suggests that the antibodies inhibit NA enzymatic activity through steric hindrance, thus limiting NA access to sialic acids when adjacent to HA on whole virions. Consistently, F(ab')2 fragments that occupied reduced area without loss of avidity or disrupted HA/NA interactions showed significantly reduced NI activity. Notably, HA stalk-binding antibodies lacking NI activity were unable to neutralize viral infection via microneutralization assays. This work suggests that NI activity is an important component of protection mediated by HA stalk-reactive antibodies.IMPORTANCE This study reports a new mechanism of protection mediated by influenza hemagglutinin stalk-reactive antibodies, i.e., inhibition of neuraminidase activity by steric hindrance, blocking access of neuraminidase to sialic acids when it abuts hemagglutinin on whole virions.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  hemagglutinin; influenza; monoclonal antibodies; neuraminidase; stalk-reactive antibody

Mesh:

Substances:

Year:  2019        PMID: 30518651      PMCID: PMC6364013          DOI: 10.1128/JVI.01526-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

2.  The Pathway to a Universal Influenza Vaccine.

Authors:  Catharine I Paules; Hilary D Marston; Robert W Eisinger; David Baltimore; Anthony S Fauci
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

3.  Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine.

Authors:  Catharine I Paules; Sheena G Sullivan; Kanta Subbarao; Anthony S Fauci
Journal:  N Engl J Med       Date:  2017-11-29       Impact factor: 91.245

4.  Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

Authors:  Ha T Nguyen; Tiffany G Sheu; Vasiliy P Mishin; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.

Authors:  Laura Couzens; Jin Gao; Kim Westgeest; Matthew Sandbulte; Vladimir Lugovtsev; Ron Fouchier; Maryna Eichelberger
Journal:  J Virol Methods       Date:  2014-09-16       Impact factor: 2.014

6.  Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.

Authors:  Kim B Westgeest; Theo M Bestebroer; Monique I J Spronken; Jin Gao; Laura Couzens; Albert D M E Osterhaus; Maryna Eichelberger; Ron A M Fouchier; Miranda de Graaf
Journal:  J Virol Methods       Date:  2015-02-21       Impact factor: 2.014

7.  Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action.

Authors:  P Palese; R W Compans
Journal:  J Gen Virol       Date:  1976-10       Impact factor: 3.891

8.  Immune history profoundly affects broadly protective B cell responses to influenza.

Authors:  Sarah F Andrews; Yunping Huang; Kaval Kaur; Lyubov I Popova; Irvin Y Ho; Noel T Pauli; Carole J Henry Dunand; William M Taylor; Samuel Lim; Min Huang; Xinyan Qu; Jane-Hwei Lee; Marlene Salgado-Ferrer; Florian Krammer; Peter Palese; Jens Wrammert; Rafi Ahmed; Patrick C Wilson
Journal:  Sci Transl Med       Date:  2015-12-02       Impact factor: 17.956

9.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

10.  Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.

Authors:  Carole J Henry Dunand; Paul E Leon; Min Huang; Angela Choi; Veronika Chromikova; Irvin Y Ho; Gene S Tan; John Cruz; Ariana Hirsh; Nai-Ying Zheng; Caitlin E Mullarkey; Francis A Ennis; Masanori Terajima; John J Treanor; David J Topham; Kanta Subbarao; Peter Palese; Florian Krammer; Patrick C Wilson
Journal:  Cell Host Microbe       Date:  2016-06-08       Impact factor: 21.023

View more
  20 in total

1.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

2.  Influenza A Virus Neuraminidase Inhibitors.

Authors:  Nongluk Sriwilaijaroen; Christopher J Vavricka; Hiromasa Kiyota; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2022

3.  Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.

Authors:  Kosuke Okuya; Reiko Yoshida; Rashid Manzoor; Shinji Saito; Tadaki Suzuki; Michihito Sasaki; Takeshi Saito; Yurie Kida; Akina Mori-Kajihara; Tatsunari Kondoh; Masahiro Sato; Masahiro Kajihara; Hiroko Miyamoto; Osamu Ichii; Hideaki Higashi; Ayato Takada
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

4.  Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq.

Authors:  Bing He; Shuning Liu; Yuanyuan Wang; Mengxin Xu; Wei Cai; Jia Liu; Wendi Bai; Shupei Ye; Yong Ma; Hengrui Hu; Huicui Meng; Tao Sun; Yanling Li; Huanle Luo; Mang Shi; Xiangjun Du; Wenjing Zhao; Shoudeng Chen; Jingyi Yang; Haipeng Zhu; Yusheng Jie; Yuedong Yang; Deyin Guo; Qiao Wang; Yuwen Liu; Huimin Yan; Manli Wang; Yao-Qing Chen
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

Review 5.  Influenza virus glycoprotein-reactive human monoclonal antibodies.

Authors:  Yanbai Li; Lili Wang; Helong Si; Zhengsen Yu; Shijun Tian; Rong Xiang; Xiaoqian Deng; Ruiying Liang; Shibo Jiang; Fei Yu
Journal:  Microbes Infect       Date:  2020-06-19       Impact factor: 2.700

6.  Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin.

Authors:  Juhye M Lee; Rachel Eguia; Seth J Zost; Saket Choudhary; Patrick C Wilson; Trevor Bedford; Terry Stevens-Ayers; Michael Boeckh; Aeron C Hurt; Seema S Lakdawala; Scott E Hensley; Jesse D Bloom
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

Review 7.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

8.  Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.

Authors:  Amanda L Skarlupka; Anne-Gaelle Bebin-Blackwell; Spencer F Sumner; Ted M Ross
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

Review 9.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

10.  Inhibiting neuraminidase can make the difference.

Authors:  Rino Rappuoli; Giuseppe Del Giudice
Journal:  J Exp Med       Date:  2019-01-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.